Skip to Content

Erwinaze (asparaginase erwinia chrysanthemi) Disease Interactions

There are 2 disease interactions with Erwinaze (asparaginase erwinia chrysanthemi):

Major

Asparaginase Erwinia Chrysanthemi (Includes Erwinaze) ↔ Pancreatitis

Severe Potential Hazard, Moderate plausibility

Applies to: Pancreatitis

The use of asparaginase Erwinia chrysanthemi is contraindicated in patients with a history of serious pancreatitis with prior L-asparaginase therapy. It is recommended to evaluate patients with symptoms compatible with pancreatitis to establish a diagnosis. In the case of mild pancreatitis, it is recommended to hold treatment until the signs and symptoms subside, and amylase levels return to normal. Discontinue treatment with this agent for severe or hemorrhagic pancreatitis manifested by abdominal pain >72 hours and amylase elevation of >= 2.0 x ULN.

Moderate

Asparaginase Erwinia Chrysanthemi (Includes Erwinaze) ↔ Diabetes

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

The use of asparaginase Erwinia chrysanthemi has been associated with glucose intolerance. Exercise caution when using this agent in patients with diabetes. It is recommended to monitor glucose levels at the start of therapy, and periodically thereafter in all patients. Administer insulin therapy as necessary in patients with hyperglycemia.

Erwinaze (asparaginase erwinia chrysanthemi) drug Interactions

There are 75 drug interactions with Erwinaze (asparaginase erwinia chrysanthemi)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide